LAS VEGAS – For many cannabis users who are trying to quit their habit, psychotherapy doesn’t seem to be enough, according to an expert.
“The addition of a pharmacological intervention might be helpful for [these people],” Dr. Frances R. Levin said at the annual psychopharmacology update held by the Nevada Psychiatric Association. “There are some promising medications out there, but we’re just at the beginning of this whole era of research.”
Dr. Francis R. Levin
Yet, while the literature is nascent, both the problem and complexity of cannabis use are growing.
According to the Substance Abuse and Mental Health Services Administration, in 1993, only 7% of those seeking treatment for substance abuse were addicted to marijuana. In 2011, just under one-fifth of all substance abuse treatment patients wanted help quitting their cannabis use. Meanwhile, in that same time period, people seeking treatment for alcohol abuse went from 57% to 39%.
Part of the rise is tied to more adolescents using the drug, said Dr. Levin, who is the Kennedy-Leavy Professor of Clinical Psychiatry at Columbia University, New York. “They are certainly overrepresented.”
With nearly 20 million Americans who say they’ve used cannabis in the past month, it is the most widely used illicit drug in the country, according to the National Survey on Drug Use and Health. However, because some states and the District of Columbia recently have legalized the use of cannabis for recreational or medical purposes, or both, Dr. Levin said the drug’s illicit status is conditional. “What’s interesting is that it’s a growing problem. Ten percent of first-time users, 17% of first-time adolescent users, and 50% of daily users will develop cannabis use disorder.”
Of particular concern are synthetic cannabinoids, said Dr. Levin, who explained that the manufactured drugs are dissolved in acetone or alcohol, and then sprayed “indiscriminately” over dried plant materials, making the concentration of THC, the main psychoactive component of cannabis, hard to gauge. In addition, the synthetic version of the drug is a full, not partial agonist. “This makes them quite dangerous,” Dr. Levin said.
Manufacturers of the synthetic drug products largely have managed to stay a step ahead of regulation by constantly creating compounds that have yet to be scheduled by the Food and Drug Administration. Although the products are often packaged and marketed as herbal incense with names like “Spice” or “K-2”, the contents of the packages typically are smoked by adolescents and by those seeking to avoid failing drug tests since, according to Dr. Levin, synthetic cannabinoids also are undetectable on THC-based drug tests.
“Even though they are called ‘cannabinoid,’ these are a very different drug,” Dr. Levin said. Episodes of paranoia, anxiety, and tachycardia that sometimes last for months have been reported in case studies. “It’s very different from what happens from smoking marijuana,” she said.
Meanwhile, over the past few decades, marijuana proper also has undergone a transformation, in large part because of advances in the way in which growers can manipulate the various cannabinoids in the different plant strains. For example, Dr. Levin said that in Colorado, where the drug is legal, it is possible to purchase marijuana with specific cannabinoids at different concentration levels, developed to “reportedly induce certain types of psychoactive effects.”
Regardless of whether users choose the more designer drug options, Dr. Levin said that compared with the 1970s when the concentration of THC in marijuana that was smoked was typically 1%-3%, now “all bets are off,” because the potency and effects are much higher. “Kids getting into smoking marijuana today could be getting concentrations of 10, 20, maybe even 40%. We have a very different drug today that these kids, as well as the adults, are being exposed to.”
When the drug is ingested orally, such as in baked goods, the concentrations absorbed by the body can be even more, although the highs are less predictable and can last as much as three times longer as when it is smoked.
Currently, the only therapies available to those who want to quit are psychotherapies. Whether pharmacologic treatments can keep pace with the spread of the disorder is in question. “I want to be optimistic, but at the moment, we just have signals,” said Dr. Levin, who said the most promising pharmacotherapeutic approaches in humans to date include gabapentin, which has been used successfully to treat alcohol dependence, and N-acetylcysteine (NAC).
Data are encouraging on the efficacy of gabapentin in adults with cannabis use disorder from a 12-week, randomized double-blind trial of 50 adults given either placebo or 1,200 mg of gabapentin divided into three daily doses (Neuropsychopharmacology 2012;37:689-98). Although the study group did not suffer severe withdrawal and did decrease their overall cannabis use, the group did not necessarily achieve complete abstinence. However, the overall executive functions scores of the study group did improve. A puzzling drawback to the trial, said Dr. Levin, was the study’s notable attrition rate. “Only 36% made it to the end of the trial. We need to find out why there was such a high dropout rate.”